Niansen Liu, MD
Psychiatry · Cleveland, TNNPI 1679578371
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 586 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 586 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$910
- Alkermes, Inc.$882
- Takeda Pharmaceuticals U.S.A., Inc.$777
- plus $4K from 20 others
What the payments were for
- Food & beverage$11,073100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 82 | $1,567 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $1,306 |
| Neurocrine Biosciences, Inc. | 66 | $1,207 |
| Teva Pharmaceuticals USA, Inc. | 53 | $910 |
| Alkermes, Inc. | 44 | $882 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $777 |
| Sunovion Pharmaceuticals Inc. | 41 | $767 |
| Lundbeck LLC | 35 | $688 |
| Vanda Pharmaceuticals Inc. | 29 | $669 |
| AbbVie(2 entities) | 40 | $614 |
| Johnson & Johnson | 22 | $465 |
| Supernus Pharmaceuticals, Inc. | 14 | $274 |
| Almatica Pharma LLC | 9 | $170 |
| Merck | 7 | $119 |
| Idorsia Pharmaceuticals US Inc | 6 | $118 |
| Jazz Pharmaceuticals Inc. | 6 | $110 |
| Harmony Biosciences LLC | 4 | $90 |
| Axsome Therapeutics, Inc. | 3 | $76 |
| Eisai Inc. | 4 | $59 |
| Shire North American Group Inc | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| Neos Therapeutics, LP | 2 | $36 |
| Bausch Health US, LLC | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Adlon Therapeutics L.p. | 1 | $14 |
How this compares
$11,093 in reported general payments places this provider in the 90th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $129,463 |
| RexultiBrexpiprazole | 47 | $81,501 |
| VraylarCariprazine Hcl | 42 | $67,008 |
| CaplytaLumateperone Tosylate | 40 | $65,299 |
| Abilify MaintenaAripiprazole | 12 | $33,254 |
| AuvelityDextromethorphan Hbr/Bupropion | 31 | $22,081 |
| TrintellixVortioxetine Hydrobromide | 22 | $13,985 |
| Quetiapine Fumarate | 577 | $10,338 |
| Olanzapine | 355 | $10,110 |
| Chlorpromazine Hcl | 38 | $10,067 |
| Aripiprazole | 334 | $9,233 |
| Alprazolam | 1,444 | $6,421 |
| Ziprasidone Hcl | 112 | $5,828 |
| Divalproex Sodium ErDivalproex Sodium | 188 | $5,694 |
| Lurasidone Hcl | 36 | $4,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $910 | $129,46311 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,567 | $114,75559 claims |
| AbbVieVraylar | $614 | $67,00842 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,306 | $65,29940 claims |
| Axsome Therapeutics, Inc.Auvelity | $76 | $22,08131 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $777 | $13,98522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Cleveland
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- John FenleyJohnson City$1.4M
- David SnowMaryville$605K
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
- George BrownJohnson City$91K
- Sricharan MoturiFranklin$82K
- Michelle CochranNashville$74K
- Daniel BoydMemphis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.